<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
      <journal-id journal-id-type="publisher-id">cam4</journal-id>
      <journal-title-group>
        <journal-title>Cancer Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2045-7634</issn>
      <issn pub-type="epub">2045-7634</issn>
      <publisher>
        <publisher-name>BlackWell Publishing Ltd</publisher-name>
        <publisher-loc>Oxford, UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25619630</article-id>
      <article-id pub-id-type="pmc">4402062</article-id>
      <article-id pub-id-type="doi">10.1002/cam4.384</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Cancer Research</subject>
          <subj-group subj-group-type="heading">
            <subject>Short Report</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Spectrum of myeloid neoplasms and immune deficiency associated with germline <italic>GATA2</italic> mutations</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mir</surname>
            <given-names>Muhammad A</given-names>
          </name>
          <xref ref-type="aff" rid="au1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kochuparambil</surname>
            <given-names>Samith T</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abraham</surname>
            <given-names>Roshini S</given-names>
          </name>
          <xref ref-type="aff" rid="au3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodriguez</surname>
            <given-names>Vilmarie</given-names>
          </name>
          <xref ref-type="aff" rid="au4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Howard</surname>
            <given-names>Matthew</given-names>
          </name>
          <xref ref-type="aff" rid="au3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hsu</surname>
            <given-names>Amy P</given-names>
          </name>
          <xref ref-type="aff" rid="au5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jackson</surname>
            <given-names>Amie E</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holland</surname>
            <given-names>Steven M</given-names>
          </name>
          <xref ref-type="aff" rid="au5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patnaik</surname>
            <given-names>Mrinal M</given-names>
          </name>
          <xref ref-type="aff" rid="au2">2</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <aff id="au1">
          <label>1</label>
          <institution>Penn State Milton S. Hershey Cancer Institute</institution>
          <addr-line>Hershey, Pennsylvania</addr-line>
        </aff>
        <aff id="au2">
          <label>2</label>
          <institution>Division of Hematology, Blood &amp; Marrow Transplant, Mayo Clinic</institution>
          <addr-line>Rochester, Minnesota</addr-line>
        </aff>
        <aff id="au3">
          <label>3</label>
          <institution>Divisions of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic</institution>
          <addr-line>Rochester, Minnesota</addr-line>
        </aff>
        <aff id="au4">
          <label>4</label>
          <institution>Division of Pediatric Hematology/Oncology, Mayo Clinic</institution>
          <addr-line>Rochester, Minnesota</addr-line>
        </aff>
        <aff id="au5">
          <label>5</label>
          <institution>Laboratory of Clinical Infectious Diseases, National Institutes of Health</institution>
          <addr-line>Bethesda, Maryland</addr-line>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence</bold> Mrinal M. Patnaik, Division of Hematology, Blood &amp; Marrow Transplant, Mayo Clinic, Rochester, MN., Tel: 507-284-3417;, Fax: 507-266-4972;, E-mail: <email>patnaik.mrinal@mayo.edu</email></corresp>
        <fn>
          <p><bold>Funding Information</bold> None declared.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <volume>4</volume>
      <issue>4</issue>
      <fpage>490</fpage>
      <lpage>499</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>9</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Guanine-adenine-thymine-adenine 2 (<italic>GATA2</italic>) mutated disorders include the recently described MonoMAC syndrome (Monocytopenia and <italic>Mycobacterium avium</italic> complex infections), DCML (dendritic cell, monocyte, and lymphocyte deficiency), familial MDS/AML (myelodysplastic syndrome/acute myeloid leukemia) (myeloid neoplasms), congenital neutropenia, congenital lymphedema (Emberger's syndrome), sensorineural deafness, viral warts, and a spectrum of aggressive infections seen across all age groups. While considerable efforts have been made to identify the mutations that characterize this disorder, pathogenesis remains a work in progress with less than 100 patients described in current literature. Varying clinical presentations offer diagnostic challenges. Allogeneic stem cell transplant remains the treatment of choice. Morbidity, mortality, and social costs due to the familial nature of the disease are considerable. We describe our experience with the disorder in three affected families and a comprehensive review of current literature.</p>
      </abstract>
      <kwd-group>
        <kwd>GATA2</kwd>
        <kwd>leukemia</kwd>
        <kwd>lymphedema</kwd>
        <kwd>MonoMAC</kwd>
        <kwd>viral warts</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>The guanine-adenine-thymine-adenine (<italic>GATA</italic>) family is comprised of six zinc-finger transcription factors that recognize approximately 7 million <italic>GATA</italic> motifs in the human genome <xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>. <italic>GATA1</italic> is instrumental in development of erythrocytes, mast cells, eosinophils, and megakaryocytes <xref rid="b3" ref-type="bibr">3</xref>&#x2013;<xref rid="b8" ref-type="bibr">8</xref> and is implicated in Down syndrome-related acute megakaryocytic leukemia and transient myeloproliferative disorder <xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b10" ref-type="bibr">10</xref>. <italic>GATA1</italic> is also associated with X-linked thrombocytopenia and dyserythropoeitic anemia (Diamond&#x2013;Blackfan anemia) <xref rid="b75" ref-type="bibr">75</xref>&#x2013;<xref rid="b77" ref-type="bibr">77</xref>. <italic>GATA2</italic>, located on 3q21 <xref rid="b11" ref-type="bibr">11</xref> is pivotal in proliferation of hematopoietic stem cells (HSC) and mutations were first described in aplastic anemia <xref rid="b12" ref-type="bibr">12</xref>&#x2013;<xref rid="b15" ref-type="bibr">15</xref>. Pedigree studies have initially recognized two mutations in <italic>GATA2</italic> in familial AML, p.T354M, and p.T355del, both in the second zinc finger (ZF-2) of <italic>GATA2</italic>
<xref rid="b16" ref-type="bibr">16</xref>&#x2013;<xref rid="b18" ref-type="bibr">18</xref>, while two other mutations; p.R308P and p.A350-N351ins8 are associated with de novo AML <xref rid="b78" ref-type="bibr">78</xref>. During erythropoiesis; GATA switching results in displacement of GATA2 by GATA1 from chromatin causing inhibition of GATA2, promoting downstream erythroid differentiation <xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b19" ref-type="bibr">19</xref>. In contrast, <italic>GATA2</italic> overexpression induces megakaryocytic differentiation in cell lines <xref rid="b20" ref-type="bibr">20</xref>. <italic>GATA2</italic> exerts an inhibiting influence on the <italic>PU.1</italic> gene which is essential for monocytic, granulocytic, and lymphoid differentiation <xref rid="b21" ref-type="bibr">21</xref>. In contrast to <italic>RUNX1</italic>, which is essential for generation of HSC, <italic>GATA2</italic> appears to be essential for HSC generation and subsequent survival <xref rid="b22" ref-type="bibr">22</xref>. Other <italic>GATA</italic> genes perform a diverse array of functions. <italic>GATA3</italic> promotes T-cell lymphopoiesis <xref rid="b23" ref-type="bibr">23</xref>&#x2013;<xref rid="b28" ref-type="bibr">28</xref> but deficiency has been associated only with hypoparathyroidism, deafness, and renal disease. <italic>GATA4</italic> has recently been implicated in childhood onset diabetes <xref rid="b29" ref-type="bibr">29</xref>. <italic>GATA 5</italic> CpG island hypermethylation in renal carcinoma appear to identify aggressive phenotypes with poor outcomes <xref rid="b30" ref-type="bibr">30</xref>. In animal models, <italic>GATA6</italic> has been shown to orchestrate cardiac muscle hypertrophy in response to pressure stress and increase hepcidin expression in inflammatory states <xref rid="b31" ref-type="bibr">31</xref>,<xref rid="b32" ref-type="bibr">32</xref>. In summary, GATA factors 1&#x2013;3 appear to be involved in hematopoiesis, while GATA 4&#x2013;6 appear to be more important for cardiac development and function <xref rid="b33" ref-type="bibr">33</xref> although expression has been demonstrated in other endodermal and mesodermal organs such as lung, liver and gonads and gut <xref rid="b34" ref-type="bibr">34</xref>.</p>
      <p>The study of germline mutations such as <italic>GATA2</italic> provides profound insights into leukemogenesis, immune dysfunction and cross-talk of seemingly diverse genetic pathways such as <italic>CEBPA, PU.1</italic>
<xref rid="b35" ref-type="bibr">35</xref>&#x2013;<xref rid="b38" ref-type="bibr">38</xref>, and <italic>RUNX1</italic>
<xref rid="b39" ref-type="bibr">39</xref>&#x2013;<xref rid="b43" ref-type="bibr">43</xref>. The clinical phenotype of germline <italic>GATA2</italic> mutations include, but is not limited to, spectrum of immune deficits such as MonoMAC syndrome <xref rid="b44" ref-type="bibr">44</xref>&#x2013;<xref rid="b46" ref-type="bibr">46</xref>, dendritic cell, monocyte and lymphoid deficiency (DCML) <xref rid="b47" ref-type="bibr">47</xref>, familial MDS (myelodysplastic syndrome)/AML (acute myeloid leukemia), and Emberger's syndrome <xref rid="b48" ref-type="bibr">48</xref>. Of note, sporadic mutations in <italic>GATA2</italic> are described and may have no familial implications as described below. Our focus in this article is the haploinsufficiency induced by spontaneous germline mutations in <italic>GATA2</italic> resulting in an autosomal dominant inheritance of diverse phenotypes <xref rid="b44" ref-type="bibr">44</xref>,<xref rid="b46" ref-type="bibr">46</xref>,<xref rid="b49" ref-type="bibr">49</xref>. The differential diagnosis of <italic>GATA-2</italic> deficiency includes other related disorders with overlapping features and are summarized in Table<xref ref-type="table" rid="tbl1">1</xref>.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Mutations/disorders in differential diagnosis of <italic>GATA2</italic> deficiency</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Familial MDS/AML <xref rid="b67" ref-type="bibr">67</xref></th>
              <th align="left" rowspan="1" colspan="1">Warts/HPV infections <xref rid="b51" ref-type="bibr">51</xref></th>
              <th align="left" rowspan="1" colspan="1">Mycobacterial infections <xref rid="b68" ref-type="bibr">68</xref>&#x2013;<xref rid="b70" ref-type="bibr">70</xref></th>
              <th align="left" rowspan="1" colspan="1">Congenital lymphedema <xref rid="b71" ref-type="bibr">71</xref>&#x2013;<xref rid="b73" ref-type="bibr">73</xref>,<xref rid="b75" ref-type="bibr">75</xref>,<xref rid="b76" ref-type="bibr">76</xref></th>
              <th align="left" rowspan="1" colspan="1">Pulmonary alveolar proteinosis <xref rid="b77" ref-type="bibr">77</xref></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">
                <italic>TERT/TERC</italic>
                <break/>
                <italic>CEBPA</italic>
                <break/>
                <italic>RUNX1</italic>
              </td>
              <td align="left" rowspan="1" colspan="1">DOCK 8<break/>CXCR4<break/>HIV/CD4&#x2193;<break/>TMC6/8<break/>SPINK5/LEKT1<break/>STK4/MST1</td>
              <td align="left" rowspan="1" colspan="1"><italic>IFNGR1</italic><break/><italic>IFNGR2</italic><break/><italic>IL12RB1</italic><break/><italic>STAT1</italic> (loss of function; AR and AD)<break/><italic>IRF8</italic><break/><italic>CYBB</italic> (macrophage-specific mutation)<break/><italic>TYK2</italic><break/><italic>ISG15</italic><break/><italic>IKKG</italic> (NEMO)</td>
              <td align="left" rowspan="1" colspan="1">
                <italic>FLT4</italic>
                <break/>
                <italic>GJC2</italic>
                <break/>
                <italic>FOXC2</italic>
                <break/>
                <italic>SOX18</italic>
                <break/>
                <italic>CCBE1</italic>
                <break/>
                <italic>PTPN14</italic>
              </td>
              <td align="left" rowspan="1" colspan="1">Anti-GM-CSF Ab<break/><italic>CSF2RB</italic></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; HPV, human papillomavirus.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec>
      <title>Case Series</title>
      <sec>
        <title>Family 1</title>
        <p>The proband is a 38-year-old Caucasian male, who presented with progressive dyspnea and fatigue of 3&#xA0;months duration and was found to have pancytopenia. A bone marrow biopsy revealed hypocellular marrow but demonstrated acute myeloid leukemia (AML) with the following cytogenetic abnormalities: t (1; 21) (q10; q10) [9]/+8[4]/46XY [7]. He received standard induction chemotherapy with idarubicin and cytarabine, and his course was complicated by an orbital fungal infection with <italic>Absidia lithemia</italic>, medically and surgically managed, following which he underwent a reduced-intensity conditioning-matched unrelated donor allogeneic hematopoietic stem cell transplant (MUD-Allo-HCT). Posttransplant course was complicated by severe refractory immune-mediated thrombocytopenia requiring a splenectomy and an orbital relapse of AML. Due to history of multiple family members being affected (Fig.<xref ref-type="fig" rid="fig02">2</xref>) by AML and extra genital warts (sister, son, and daughter), congenital lymphedema (son), and cytopenias (sister) a work-up for familial bone marrow failure syndromes was carried out. <italic>GATA2</italic> mutation analysis performed at the National Institutes of Health (NIH) confirmed the presence of a missense mutation (1339A&gt;C, p S447R) in the patient, a female sibling, a son, and a daughter. The female sibling with MDS and viral warts also underwent MUD-Allo-HSCT (hematopoietic stem cell transplant) and remains symptom-free 14&#xA0;months posttransplant. The probands son and daughter also underwent MUD allogeneic HSCT and are doing very well more than 12&#xA0;months posttransplant. Patient characteristics and outcomes are shown in Table<xref ref-type="table" rid="tbl2">2</xref>.</p>
        <table-wrap id="tbl2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Clinical characteristics and outcomes of patients with GATA2 mutations that underwent allogeneic stem cell transplantation</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">No.</th>
                <th align="left" rowspan="1" colspan="1">Diagnosis Age/Sex</th>
                <th align="left" rowspan="1" colspan="1">Cytogenetics/GATA2 mutation</th>
                <th align="left" rowspan="1" colspan="1">Associated features</th>
                <th align="left" rowspan="1" colspan="1">Prior Rx</th>
                <th align="left" rowspan="1" colspan="1">HCT-CI</th>
                <th align="left" rowspan="1" colspan="1">CMV</th>
                <th align="left" rowspan="1" colspan="1">Regimen</th>
                <th align="left" rowspan="1" colspan="1">ABO/HLA</th>
                <th align="left" rowspan="1" colspan="1">GVHD Prop</th>
                <th align="left" rowspan="1" colspan="1">aGVHD Status</th>
                <th align="left" rowspan="1" colspan="1">Complications</th>
                <th align="left" rowspan="1" colspan="1">Day 30 Chimerism /Marrow</th>
                <th align="left" rowspan="1" colspan="1">Day 100 Chimerism /Marrow</th>
                <th align="left" rowspan="1" colspan="1">Last follow up (Days)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">AML<break/>38/M</td>
                <td align="left" rowspan="1" colspan="1">46,XY, t(1;21) [9] +8[4]46,XY [7]<break/>S447R</td>
                <td align="left" rowspan="1" colspan="1">NK/B-cell def<break/>Viral warts<break/>Hydrocele</td>
                <td align="left" rowspan="1" colspan="1">Idarubicin Cytarabine</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">D+<break/>R+</td>
                <td align="left" rowspan="1" colspan="1">Fludarabine TBI (200)</td>
                <td align="left" rowspan="1" colspan="1">ABO&#x2212; mismatch HLA 9/10</td>
                <td align="left" rowspan="1" colspan="1">Tacrolimus<break/>MTX</td>
                <td align="left" rowspan="1" colspan="1">GI<break/>Grade 1</td>
                <td align="left" rowspan="1" colspan="1">E.Faecalis<break/>CMV<break/>Anti-platelet antibodies/Thrombocytopenia</td>
                <td align="left" rowspan="1" colspan="1">100%<break/>Donor<break/>30% Hypo-<break/>Cellular</td>
                <td align="left" rowspan="1" colspan="1">100% Donor<break/>30% Hypo-<break/>Cellular</td>
                <td align="left" rowspan="1" colspan="1">356<break/>(extra medullary relapse day 307)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">2</td>
                <td align="left" rowspan="1" colspan="1">MDS<break/>35/F</td>
                <td align="left" rowspan="1" colspan="1">S447R</td>
                <td align="left" rowspan="1" colspan="1">NK/B-cell def<break/>Viral warts<break/>Infertility</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">D&#x2212;<break/>R+</td>
                <td align="left" rowspan="1" colspan="1">Busulfan<break/>Cytoxan</td>
                <td align="left" rowspan="1" colspan="1">ABO&#x2212; match<break/>HLA 10/10</td>
                <td align="left" rowspan="1" colspan="1">Tacrolimus<break/>MTX</td>
                <td align="left" rowspan="1" colspan="1">Skin<break/>Grade 1</td>
                <td align="left" rowspan="1" colspan="1">CMV</td>
                <td align="left" rowspan="1" colspan="1">100% Donor<break/>30% Hypocellular</td>
                <td align="left" rowspan="1" colspan="1">100% Donor<break/>60% Hypocellular</td>
                <td align="left" rowspan="1" colspan="1">208</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">3</td>
                <td align="left" rowspan="1" colspan="1">MDS<break/>10/F</td>
                <td align="left" rowspan="1" colspan="1">S447R</td>
                <td align="left" rowspan="1" colspan="1">NK/B-cell def<break/>Viral warts</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">D&#x2212;<break/>R+</td>
                <td align="left" rowspan="1" colspan="1">Cytoxan,<break/>TBI<break/>Alemtuzumab</td>
                <td align="left" rowspan="1" colspan="1">ABO&#x2212; match<break/>HLA 9/10</td>
                <td align="left" rowspan="1" colspan="1">Tacrolimus<break/>MTX</td>
                <td align="left" rowspan="1" colspan="1">Skin<break/>Grade 1</td>
                <td align="left" rowspan="1" colspan="1">C.difficile</td>
                <td align="left" rowspan="1" colspan="1">100% Donor<break/>30% Hypo-<break/>Cellular</td>
                <td align="left" rowspan="1" colspan="1">100% Donor<break/>20% Hypo-<break/>Cellular</td>
                <td align="left" rowspan="1" colspan="1">247</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">Chronic Neutropenia<break/>7/M</td>
                <td align="left" rowspan="1" colspan="1">S447R</td>
                <td align="left" rowspan="1" colspan="1">NK/B cell def<break/>Viral warts<break/>Emberger's syndrome<break/>Pulmonary stenosis</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">D&#x2212;<break/>R+</td>
                <td align="left" rowspan="1" colspan="1">Cytoxan,<break/>TBI<break/>Alemtuzumab</td>
                <td align="left" rowspan="1" colspan="1">ABO&#x2212; match<break/>HLA 10/10</td>
                <td align="left" rowspan="1" colspan="1">Tacrolimus</td>
                <td align="left" rowspan="1" colspan="1">&#x2013;</td>
                <td align="left" rowspan="1" colspan="1">&#x2013;</td>
                <td align="left" rowspan="1" colspan="1">Pending<break/>30% Hypo cellular</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
                <td align="left" rowspan="1" colspan="1">31</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MDS, myelodysplastic syndrome; AML, acute myeloid leukemia.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig id="fig01" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Genotype/phenotype relations of GATA2 mutations.</p>
          </caption>
          <graphic xlink:href="cam40004-0490-f1"/>
        </fig>
      </sec>
      <sec>
        <title>Family 2</title>
        <p>Family 2 was discovered by the birth of a newborn with dysmorphic features (head size larger than stomach) resulting in a cytogenetic examination in infancy with identification of deletion 3q13.2-q21.3, which includes the <italic>GATA2</italic> gene. The child exhibited monocytopenia without lymphopenia or neutropenia. Dendritic cell activity was not assessed for. The parents were tested and did not have the same gene defect. She is being followed with monthly blood tests and has not demonstrated any systemic infections or signs of MDS/AML although cognitive development appears to be delayed.</p>
        <fig id="fig02" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Family Tree of Proband 1 with the GATA2 c.1339A&gt;C.pS447R mutation.</p>
          </caption>
          <graphic xlink:href="cam40004-0490-f2"/>
        </fig>
        <fig id="fig03" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Years post allogeneic HSCT for GATA2 mutation Spinner et al. [<xref rid="b53" ref-type="bibr">53</xref>]HSCT, 5 hematopoietic stem cell transplant.</p>
          </caption>
          <graphic xlink:href="cam40004-0490-f3"/>
        </fig>
      </sec>
      <sec>
        <title>Family 3</title>
        <p>In Family 3, the proband is a Caucasian female who presented at age 17&#xA0;years with abdominal pain, hemoptysis, and mild pancytopenia. A CT scan revealed mild diffuse thoracic and abdominal lymphadenopathy. A detailed evaluation found acute Epstein&#x2013;Barr virus (EBV) infection. A bone marrow biopsy was mildly hypocellular with mild erythroid hypoplasia and megakaryocytic hyperplasia with atypia. The cytogenetics were 46, XX <xref rid="b20" ref-type="bibr">20</xref>. She had a history of recurrent episodes of hidradenitis suppurativa, skin abscesses, folliculitis, otitis media, and throat infections. Several years later, she was initiated on therapy with pegylated G-CSF. In spite of this, otitis media and abscesses continued. Two years later, she presented with a hypercatabolic state, with progressive hepato-splenomegaly and constitutional features. A bone marrow biopsy demonstrated progressive megakaryocytic atypia. While cytogenetics were once again normal, however, a MDS-fluorescence in situ hybridization (FISH) panel identified a deletion of -3q21 in 99% of analyzed nuclei. A phytohemagglutinin-stimulated karyotyping of peripheral blood lymphocytes also demonstrated the -3q21 (RPN1 deletion) in 99% of analyzed nuclei. <italic>GATA2</italic> is located within this region, Expression studies confirmed <italic>GATA2</italic> haploinsufficiency. She is awaiting a donor for a MUD-HSCT.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <sec>
        <title>MonoMAC syndrome and DCML deficiency</title>
        <p>The terms MonoMAC and DCML are synonymous, in terms of the genetic etiology, and refer to a primary immunodeficiency with predisposition to MDS/AML. MonoMAC refers to a recently described syndrome of <italic>MONO</italic>cytopenia and <italic>M</italic>ycobacterium <italic>A</italic>vium <italic>C</italic>omplex infections characterized by germline <italic>GATA2</italic> mutations <xref rid="b44" ref-type="bibr">44</xref>,<xref rid="b46" ref-type="bibr">46</xref>. DCML, also caused by germline <italic>GATA2</italic> mutations refers specifically to the cytopenias frequently seen in most patients&#x2014;DCML deficiency (both B and NK cell) <xref rid="b50" ref-type="bibr">50</xref>. Two independent groups studied 24 individuals with these syndromes and reported similar mutations noted above in familial syndromes (T354M and T355 del). The scope of immune deficiency in this group is vast and not limited to mycobacterial infections. Opportunistic viral (disseminated human papillomavirus [HPV] and HPV-associated squamous cell carcinoma) <xref rid="b51" ref-type="bibr">51</xref>, parasitic and fungal infections, as well as pulmonary alveolar proteinosis (<italic>GATA2</italic> is known to influence the phagocytic activity of pulmonary alveolar macrophages) can be seen <xref rid="b52" ref-type="bibr">52</xref>. A majority of patients with <italic>GATA2</italic> mutations eventually show deficiency of B lymphocytes, NK cells, CD4 lymphocytes, and monocytes <xref rid="b53" ref-type="bibr">53</xref>.</p>
        <sec>
          <title>Emberger's syndrome</title>
          <p>Emberger's Syndrome is primary lymphedema with cutaneous warts, deafness, and a propensity to develop MDS/AML. Intact <italic>GATA2</italic> function is required for proper lymphatic vascular development during embryogenesis in mice <xref rid="b54" ref-type="bibr">54</xref>. Ostergaard and colleagues identified eight mutations in <italic>GATA2</italic> in three patients with this syndrome by whole-exome sequencing identifying this mutation as the only common denominator between the group <xref rid="b48" ref-type="bibr">48</xref>. At least 1 other patient with propensity to varicella zoster and salmonella infections has been reported <xref rid="b48" ref-type="bibr">48</xref>. Complications secondary to prolonged lymphedema such as secondary cellulitis and deep vein thrombosis (DVT) are frequent <xref rid="b53" ref-type="bibr">53</xref>. Null mutations in <italic>GATA2</italic> appear to be associated with severe viral infections and lymphedema <xref rid="b52" ref-type="bibr">52</xref>.</p>
        </sec>
      </sec>
      <sec>
        <title>Familial MDS/AML</title>
        <p><italic>GATA2</italic> overexpression has been documented in one-third to one half of nonfamilial AML and correlates with a poor prognosis with shorter overall and event-free survival when treated with standard chemotherapy <xref rid="b55" ref-type="bibr">55</xref>,<xref rid="b56" ref-type="bibr">56</xref>. Of the original four families with <italic>GATA2</italic> mutations, described by Hahn et&#xA0;al. with MDS/AML, three had the T354M mutation, and one had deletion T355. Both mutations occurred in the second zinc finger (ZF) of GATA2 (<xref ref-type="fig" rid="fig01">Fig 1</xref>). In the T354 mutation families, all members had the mutation but not all had developed hematological disease at least by the time of reporting <xref rid="b16" ref-type="bibr">16</xref>. Bone marrow biopsies are typically hypocellular in contrast to the common MDS marrow picture, with abundant atypical megakaryocytes in &gt;90% patients <xref rid="b53" ref-type="bibr">53</xref>. Some patients have also fulfilled the diagnostic criteria for CMML (chronic myelomonocytic leukemia) and LGL (large granular lymphocytic leukemia) suggesting overlap syndromes <xref rid="b53" ref-type="bibr">53</xref>. Other acquired mutations such as <italic>ASXL1</italic> may herald the development of AML <xref rid="b57" ref-type="bibr">57</xref>. Increased levels of <italic>FLT3</italic> ligand have also been reported to be associated with clinical progression <xref rid="b58" ref-type="bibr">58</xref>.</p>
        <sec>
          <title>Chronic myeloid leukemia</title>
          <p>A novel <italic>GATA2</italic> mutation <italic>L359V</italic> has been found in nearly 10% of patients with accelerated or blast phase CML, but not CLL or ALL <xref rid="b59" ref-type="bibr">59</xref>,<xref rid="b60" ref-type="bibr">60</xref>. This is thought to be mediated through <italic>PU.1</italic> inhibition. It is interesting to note that GATA2 overexpression or the <italic>L359V gain-of-function</italic> mutation have been associated with AML and CML, respectively; whereas <italic>loss-of-function</italic> mutation of GATA2 such as <italic>T354M</italic> have been linked to MDS. L359 and T354 located in the same region on the second zinc finger of GATA2 thus highlighting the vital role GATA2 plays in hemostasis of myeloid precursors.</p>
        </sec>
      </sec>
      <sec>
        <title>Aplastic anemia</title>
        <p>Expression of GATA-2 mRNA in purified CD34-positive cells was significantly decreased in aplastic anemia compared with normal subjects when examined by immunocytochemical analysis <xref rid="b61" ref-type="bibr">61</xref>. The changes extend further to stromal cells, with lower expression of GATA2 in patients with aplastic anemia when compared to controls by RT-PCR-ELISA <xref rid="b62" ref-type="bibr">62</xref>. <italic>GATA-2</italic> is instrumental in both hematopoiesis and adipogenesis. Overexpression of peroxisome proliferator-activated receptor-gamma (PPAR-<italic>&#x3B3;</italic>, an adipogenic factor) and underexpression of GATA2 by mesenchymal stem cells may explain fatty marrow replacement in AA patients <xref rid="b63" ref-type="bibr">63</xref>.</p>
      </sec>
      <sec>
        <title>Pediatric neutropenia</title>
        <p>A high frequency of <italic>GATA2</italic> mutations has been reported in pediatric patients with mild chronic neutropenia <xref rid="b64" ref-type="bibr">64</xref>. Analysis of French Neutropenia registry data revealed chronic familial neutropenia in seven families predisposing to MDS/AML associated with <italic>GATA2</italic> mutations that included a complete deletion of <italic>GATA2</italic> locus as well as additional mutations (p.R396Q, R204X, R330X, E224X, A372T, and M388V) <xref rid="b64" ref-type="bibr">64</xref>.</p>
      </sec>
      <sec>
        <title>Pulmonary disease</title>
        <p>Ventilation-diffusion defects can be demonstrated in about two-thirds of <italic>GATA2</italic>-deficient patients while pulmonary hypertension (PAH) and pulmonary alveolar proteinosis (PAP) are some of the rare manifestations occurring in &lt;20% in one series <xref rid="b53" ref-type="bibr">53</xref>. PAP in GATA2 deficiency is not due to GM-CSF-(Granulocyte Monocyte- Colony Stimulating Factor) autoantibodies and is refractory to GM-CSF inhalational and subcutaneous therapy <xref rid="b53" ref-type="bibr">53</xref>.</p>
      </sec>
    </sec>
    <sec>
      <title>Treatment</title>
      <sec>
        <title>Immune deficiency</title>
        <p>Allogeneic HSCT remains the main therapy for <italic>GATA2</italic>-deficient patients with immunodeficiency. Timing of HSCT for immune deficiency alone is less well defined as compared to MDS/AML and should focus on risk-benefit ratios for the individual and the family. The incidence of HPV, mycobacterial, and fungal infections decreases considerably after successful allogeneic HSCT <xref rid="b53" ref-type="bibr">53</xref>,<xref rid="b65" ref-type="bibr">65</xref>. Notably, it may take more than 3.5&#xA0;years for reversal of phenotype and full immune reconstitution of B, NK, and monocyte populations <xref rid="b66" ref-type="bibr">66</xref>. This may be especially problematic with delayed engraftment typical of umbilical cord grafts. Both PAP and PAH also respond well to HSCT and repeated lung infections or declining lung function should be considered an indication in clinical context <xref rid="b53" ref-type="bibr">53</xref>. Earlier transplantation, before organ dysfunction ensues, results in less morbidity and mortality.</p>
      </sec>
      <sec>
        <title>MDS/AML</title>
        <p>Allogeneic HCT remains the only treatment with favorable responses in <italic>GATA2</italic>-mutated MDS/AML (Fig.<xref ref-type="fig" rid="fig03">3</xref>). In the NIH experience, 21 patients were transplanted for either hematological (MDS/AML) or immunological indications (age 15&#x2013;49&#xA0;years) with good responses (Fig.<xref ref-type="fig" rid="fig01">1</xref>). Of note, half the patients who were not transplanted passed away by age 40 <xref rid="b51" ref-type="bibr">51</xref>. A similar NIH experience further outlined use of conditioning regimens for nonmyeloablative allogeneic HCT <xref rid="b66" ref-type="bibr">66</xref>. Donors included fully matched related and unrelated donors (conditioning-fludarabine&#xA0;+&#xA0;total body radiation 200&#xA0;cGy) and alternative sources such as umbilical cord blood and haploidentical bone marrow (fludarabine&#xA0;+&#xA0;cyclophosphamide and total body irradiation 200&#xA0;cGy, with posttransplant cyclophosphamide for T-cell replete grafts). Busulfan was later added for a more robust eradication of the <italic>GATA2</italic> clone. Azithromycin was started before and continued for 1&#xA0;year posttransplant due to increased propensity to nontuberculous mycobacterial (NTM) infections, in addition to standard prophylaxis. No NTM infections during or after transplant were reported using prophylaxis. Overall survival was 57% at 36&#xA0;months. Our patient characteristics and outcomes are shown in Table<xref ref-type="table" rid="tbl2">2</xref>. Tacrolimus was used for graft versus host disease prophylaxis. All four patients have engrafted with 100% donor chimerisms (CD3 and CD33 fractions). One patient had CMV-Cytomegalovirus reactivation and refractory thrombocytopenia which failed to improve despite splenectomy. Three developed acute GVHD and one had chronic GVHD involving esophagus with dysphagia and strictures that improved with steroids.</p>
        <p>Two clinical trials are currently recruiting patients for myeloablative and reduced-intensity conditioning allogeneic HSCT for <italic>GATA2</italic> mutations and enrollment is encouraged whenever feasible (NCT01861106 and NCT00923364 at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrails.gov">www.clinicaltrails.gov</ext-link>).</p>
      </sec>
      <sec>
        <title>Genetic counseling</title>
        <p>Early genetic diagnosis and screening is paramount <xref rid="b53" ref-type="bibr">53</xref>. Patients and families should be seen in conjunction with a geneticist. Suggested screening categories are listed in Table<xref ref-type="table" rid="tbl3">3</xref>. Variable phenotypes resulting from different GATA2 mutations are listed in Table<xref ref-type="table" rid="tbl4">4</xref>.</p>
        <table-wrap id="tbl3" position="float">
          <label>Table 3</label>
          <caption>
            <p>Suggested screening categories for <italic>GATA2</italic> mutation</p>
          </caption>
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pediatric neutropenia</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Monocytopenia</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">B-cell or NK cell cytopenia</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Dendritic cell deficiency</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">MDS with hypocellular bone marrow</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Familial MDS/AML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">PAP in absence of anti-GM-CSF autoantibodies</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Recurrent extra genital HPV warts or severe refractory genital HPV</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Severe viral infection (HSV, EBV)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Lymphedema, often later onset</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Sensorineural deafness with immunodeficiency</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Disseminated nontuberculous mycobacteria (NTM)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Disseminated or severe fungal infections</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pulmonary NTM without bronchiectasis</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Modified from Spinner et&#xA0;al. <xref rid="b53" ref-type="bibr">53</xref>. MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; HPV, human papillomavirus; PAP, pulmonary alveolar proteinosis; EBV, Epstein&#x2013;Barr virus.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="tbl4" position="float">
          <label>Table 4</label>
          <caption>
            <p>Mutations of <italic>GATA2</italic> resulting in variable phenotypes (Fig.<xref ref-type="fig" rid="fig03">3</xref>) <xref rid="b78" ref-type="bibr">78</xref></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Mutation type</th>
                <th align="left" rowspan="1" colspan="1">AA location</th>
                <th align="left" rowspan="1" colspan="1">Phenotype</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Nonsense</td>
                <td align="left" rowspan="1" colspan="1">337(ZF1)</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="7" colspan="1">Missense</td>
                <td align="left" rowspan="1" colspan="1">254</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">354(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">Familial MDS/AML, MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">361(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">371(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">373(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">396(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">398(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="9" colspan="1">Frameshift</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">78</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">81</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">105</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">194</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">200</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">259</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">317(ZF1)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">341(ZF1)</td>
                <td align="left" rowspan="1" colspan="1">Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="2" colspan="1">In-frame insertion or deletion</td>
                <td align="left" rowspan="1" colspan="1">355(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">Familial MDS/AML</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">361(ZF2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML, Emberger syndrome</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Large deletion</td>
                <td align="left" rowspan="1" colspan="1">340&#x2013;381(ZF1 &amp; 2)</td>
                <td align="left" rowspan="1" colspan="1">MonoMAC/DCML</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; DCML, dendritic cell, monocyte, and lymphocyte.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec>
      <title>Conflicts of Interest</title>
      <p>None declared.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simon</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Gotta have GATA</article-title>
          <source>Nat. Genet</source>
          <year>1995</year>
          <volume>11</volume>
          <fpage>9</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">7550322</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bresnick</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Katsumura</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Perkins</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies</article-title>
          <source>Nucleic Acids Res</source>
          <year>2012</year>
          <volume>40</volume>
          <fpage>5819</fpage>
          <lpage>5831</lpage>
          <pub-id pub-id-type="pmid">22492510</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pevny</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>D'Agati</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1</article-title>
          <source>Nature</source>
          <year>1991</year>
          <volume>349</volume>
          <fpage>257</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="pmid">1987478</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simon</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Pevny</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wiles</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Costantini</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells</article-title>
          <source>Nat. Genet</source>
          <year>1992</year>
          <volume>1</volume>
          <fpage>92</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">1302015</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1995</year>
          <volume>92</volume>
          <fpage>9623</fpage>
          <lpage>9627</lpage>
          <pub-id pub-id-type="pmid">7568185</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Browne</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Cunniff</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Goff</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>12355</fpage>
          <lpage>12358</lpage>
          <pub-id pub-id-type="pmid">8901585</pub-id>
        </element-citation>
      </ref>
      <ref id="b7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cantor</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Browne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo</article-title>
          <source>J. Exp. Med</source>
          <year>2002</year>
          <volume>195</volume>
          <fpage>1387</fpage>
          <lpage>1395</lpage>
          <pub-id pub-id-type="pmid">12045237</pub-id>
        </element-citation>
      </ref>
      <ref id="b8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Shivdasani</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>McDevitt</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Transcription factor GATA-1 in megakaryocyte development</article-title>
          <source>Stem Cells</source>
          <year>1998</year>
          <volume>16</volume>
          <issue>Suppl. 2</issue>
          <fpage>79</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">11012179</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caldwell</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dombkowski</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Matherly</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic leukemia</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e68601</fpage>
          <pub-id pub-id-type="pmid">23874683</pub-id>
        </element-citation>
      </ref>
      <ref id="b10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cabelof</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>HV</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>van Remmen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matherly</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>2753</fpage>
          <lpage>2763</lpage>
          <pub-id pub-id-type="pmid">19633202</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vicente</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Conchillo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garcia-Sanchez</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Odero</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>The role of the GATA2 transcription factor in normal and malignant hematopoiesis</article-title>
          <source>Crit. Rev. Oncol. Hematol</source>
          <year>2012</year>
          <volume>82</volume>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">21605981</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harigae</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>GATA transcription factors and hematological diseases</article-title>
          <source>Tohoku J. Exp. Med</source>
          <year>2006</year>
          <volume>210</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">16960339</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ling</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Ottersbach</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>van Hamburg</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Oziemlak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells</article-title>
          <source>J. Exp. Med</source>
          <year>2004</year>
          <volume>200</volume>
          <fpage>871</fpage>
          <lpage>882</lpage>
          <pub-id pub-id-type="pmid">15466621</pub-id>
        </element-citation>
      </ref>
      <ref id="b14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rosenblatt</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>An early haematopoietic defect in mice lacking the transcription factor GATA-2</article-title>
          <source>Nature</source>
          <year>1994</year>
          <volume>371</volume>
          <fpage>221</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">8078582</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>FY</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>3636</fpage>
          <lpage>3643</lpage>
          <pub-id pub-id-type="pmid">9160668</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hahn</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Carmichael</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Wilkins</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Brautigan</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XC</given-names>
            </name>
          </person-group>
          <article-title>Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia</article-title>
          <source>Nat. Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>1012</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">21892162</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kazenwadel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Secker</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Wildin</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Cuellar-Rodriguez</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>119</volume>
          <fpage>1283</fpage>
          <lpage>1291</lpage>
          <pub-id pub-id-type="pmid">22147895</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bodor</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Renneville</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Charazac</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iqbal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Etancelin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival</article-title>
          <source>Haematologica</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>890</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="pmid">22271902</pub-id>
        </element-citation>
      </ref>
      <ref id="b19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bresnick</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Keles</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>GATA switches as developmental drivers</article-title>
          <source>J. Biol. Chem</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>31087</fpage>
          <lpage>31093</lpage>
          <pub-id pub-id-type="pmid">20670937</pub-id>
        </element-citation>
      </ref>
      <ref id="b20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Visvader</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Crossley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line</article-title>
          <source>Mol. Cell. Biol</source>
          <year>1995</year>
          <volume>15</volume>
          <fpage>634</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">7823932</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chou</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Khandros</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Vakoc</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>983</fpage>
          <lpage>994</lpage>
          <pub-id pub-id-type="pmid">19491391</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Pater</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kaimakis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vink</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Yokomizo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamada-Inagawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>van der Linden</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Gata2 is required for HSC generation and survival</article-title>
          <source>J. Exp. Med</source>
          <year>2013</year>
          <volume>210</volume>
          <fpage>2843</fpage>
          <lpage>2850</lpage>
          <pub-id pub-id-type="pmid">24297996</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Truitt</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Ting</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Leiden</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Glimcher</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>Critical roles for transcription factor GATA-3 in thymocyte development</article-title>
          <source>Immunity</source>
          <year>2003</year>
          <volume>19</volume>
          <fpage>863</fpage>
          <lpage>875</lpage>
          <pub-id pub-id-type="pmid">14670303</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ting</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Leiden</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Transcription factor GATA-3 is required for development of the T-cell lineage</article-title>
          <source>Nature</source>
          <year>1996</year>
          <volume>384</volume>
          <fpage>474</fpage>
          <lpage>478</lpage>
          <pub-id pub-id-type="pmid">8945476</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Brigl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Besra</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Gumperz</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>GATA-3 regulates the development and function of invariant NKT cells</article-title>
          <source>J. Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <fpage>6650</fpage>
          <lpage>6659</lpage>
          <pub-id pub-id-type="pmid">17082577</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>BY</given-names>
            </name>
            <name>
              <surname>Sabadini</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Parisini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Truitt</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>Distinct structural requirements of GATA-3 for the regulation of thymocyte and Th2 cell differentiation</article-title>
          <source>J. Immunol</source>
          <year>2008</year>
          <volume>180</volume>
          <fpage>1050</fpage>
          <lpage>1059</lpage>
          <pub-id pub-id-type="pmid">18178845</pub-id>
        </element-citation>
      </ref>
      <ref id="b27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pai</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Truitt</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>1993</fpage>
          <lpage>1998</lpage>
          <pub-id pub-id-type="pmid">14769923</pub-id>
        </element-citation>
      </ref>
      <ref id="b28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
          <article-title>GATA-3 regulates the homeostasis and activation of CD8+ T cells</article-title>
          <source>J. Immunol</source>
          <year>2013</year>
          <volume>190</volume>
          <fpage>428</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">23225883</pub-id>
        </element-citation>
      </ref>
      <ref id="b29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw-Smith</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Franco</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Batlle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Borowiec</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GATA4 mutations are a cause of neonatal and childhood-onset diabetes</article-title>
          <source>Diabetes</source>
          <year>2014</year>
          <volume>63</volume>
          <fpage>2888</fpage>
          <lpage>2894</lpage>
          <pub-id pub-id-type="pmid">24696446</pub-id>
        </element-citation>
      </ref>
      <ref id="b30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dubrowinskaja</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kogosov</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hennenlotter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>von Klot</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma</article-title>
          <source>BMC Cancer</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>101</fpage>
          <pub-id pub-id-type="pmid">24533449</pub-id>
        </element-citation>
      </ref>
      <ref id="b31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bagu</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Layoun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Calve</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Friend of GATA and GATA-6 modulate the transcriptional up-regulation of hepcidin in hepatocytes during inflammation</article-title>
          <source>Biometals</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>1051</fpage>
          <lpage>1065</lpage>
          <pub-id pub-id-type="pmid">24179092</pub-id>
        </element-citation>
      </ref>
      <ref id="b32">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Berlo</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Aronow</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Molkentin</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Parsing the roles of the transcription factors GATA-4 and GATA-6 in the adult cardiac hypertrophic response</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e84591</fpage>
          <pub-id pub-id-type="pmid">24391969</pub-id>
        </element-citation>
      </ref>
      <ref id="b33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laforest</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Nemer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GATA5 interacts with GATA4 and GATA6 in outflow tract development</article-title>
          <source>Dev. Biol</source>
          <year>2011</year>
          <volume>358</volume>
          <fpage>368</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="pmid">21839733</pub-id>
        </element-citation>
      </ref>
      <ref id="b34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molkentin</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression</article-title>
          <source>J. Biol. Chem</source>
          <year>2000</year>
          <volume>275</volume>
          <fpage>38949</fpage>
          <lpage>38952</lpage>
          <pub-id pub-id-type="pmid">11042222</pub-id>
        </element-citation>
      </ref>
      <ref id="b35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grigorakaki</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morceau</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chateauvieux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dicato</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Diederich</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor alpha-mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression</article-title>
          <source>Biochem. Pharmacol</source>
          <year>2011</year>
          <volume>82</volume>
          <fpage>156</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">21501595</pub-id>
        </element-citation>
      </ref>
      <ref id="b36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitajima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>107</volume>
          <fpage>1857</fpage>
          <lpage>1863</lpage>
          <pub-id pub-id-type="pmid">16254139</pub-id>
        </element-citation>
      </ref>
      <ref id="b37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>DeKoter</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Lancki</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Gurish</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates</article-title>
          <source>Immunity</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>665</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="pmid">12433372</pub-id>
        </element-citation>
      </ref>
      <ref id="b38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Behre</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Iwama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wara-Aswapati</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Radomska</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>8705</fpage>
          <lpage>8710</lpage>
          <pub-id pub-id-type="pmid">10411939</pub-id>
        </element-citation>
      </ref>
      <ref id="b39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossmann</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Haferlach</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nadarajah</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fasan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weissmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roller</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis</article-title>
          <source>Br. J. Haematol</source>
          <year>2013</year>
          <volume>161</volume>
          <fpage>649</fpage>
          <lpage>658</lpage>
          <pub-id pub-id-type="pmid">23521373</pub-id>
        </element-citation>
      </ref>
      <ref id="b40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandoli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Wierenga</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Riahi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Franci</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>770</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="pmid">24002588</pub-id>
        </element-citation>
      </ref>
      <ref id="b41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nottingham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Jarratt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Speck</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Prabhakar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <fpage>4188</fpage>
          <lpage>4197</lpage>
          <pub-id pub-id-type="pmid">17823307</pub-id>
        </element-citation>
      </ref>
      <ref id="b42">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tijssen</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cvejic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hannah</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Forrai</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators</article-title>
          <source>Dev. Cell</source>
          <year>2011</year>
          <volume>20</volume>
          <fpage>597</fpage>
          <lpage>609</lpage>
          <pub-id pub-id-type="pmid">21571218</pub-id>
        </element-citation>
      </ref>
      <ref id="b43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Timms</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Kinston</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Oram</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Landry</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Gfi1 expression is controlled by five distinct regulatory regions spread over 100 kilobases, with Scl/Tal1, Gata2, PU.1, Erg, Meis1, and Runx1 acting as upstream regulators in early hematopoietic cells</article-title>
          <source>Mol. Cell. Biol</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>3853</fpage>
          <lpage>3863</lpage>
          <pub-id pub-id-type="pmid">20516218</pub-id>
        </element-citation>
      </ref>
      <ref id="b44">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Lemieux</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <article-title>Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>2653</fpage>
          <lpage>2655</lpage>
          <pub-id pub-id-type="pmid">21670465</pub-id>
        </element-citation>
      </ref>
      <ref id="b45">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camargo</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Lobo</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Zerbe</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Wormser</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature</article-title>
          <source>Clin. Infect. Dis</source>
          <year>2013</year>
          <volume>57</volume>
          <fpage>697</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">23728141</pub-id>
        </element-citation>
      </ref>
      <ref id="b46">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vinh</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Uzel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Olivier</surname>
              <given-names>KN</given-names>
            </name>
          </person-group>
          <article-title>Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>115</volume>
          <fpage>1519</fpage>
          <lpage>1529</lpage>
          <pub-id pub-id-type="pmid">20040766</pub-id>
        </element-citation>
      </ref>
      <ref id="b47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Honma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia</article-title>
          <source>Eur. J. Pediatr</source>
          <year>2012</year>
          <volume>171</volume>
          <fpage>1273</fpage>
          <lpage>1276</lpage>
          <pub-id pub-id-type="pmid">22430350</pub-id>
        </element-citation>
      </ref>
      <ref id="b48">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostergaard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Connell</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Steward</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Woollard</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)</article-title>
          <source>Nat. Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>929</fpage>
          <lpage>931</lpage>
          <pub-id pub-id-type="pmid">21892158</pub-id>
        </element-citation>
      </ref>
      <ref id="b49">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Falcone</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Sanalkumar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hickstein</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>121</volume>
          <fpage>3830</fpage>
          <lpage>3837</lpage>
          <pub-id pub-id-type="pmid">23502222</pub-id>
        </element-citation>
      </ref>
      <ref id="b50">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickinson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bigley</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Reynard</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Haniffa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>2656</fpage>
          <lpage>2658</lpage>
          <pub-id pub-id-type="pmid">21765025</pub-id>
        </element-citation>
      </ref>
      <ref id="b51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leiding</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Warts and all: human papillomavirus in primary immunodeficiencies</article-title>
          <source>J. Allergy Clin. Immunol</source>
          <year>2012</year>
          <volume>130</volume>
          <fpage>1030</fpage>
          <lpage>1048</lpage>
          <pub-id pub-id-type="pmid">23036745</pub-id>
        </element-citation>
      </ref>
      <ref id="b52">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lasbury</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Durant</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts</article-title>
          <source>Infect. Immun</source>
          <year>2003</year>
          <volume>71</volume>
          <fpage>4943</fpage>
          <lpage>4952</lpage>
          <pub-id pub-id-type="pmid">12933836</pub-id>
        </element-citation>
      </ref>
      <ref id="b53">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spinner</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Zerbe</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>123</volume>
          <fpage>809</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="pmid">24227816</pub-id>
        </element-citation>
      </ref>
      <ref id="b54">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Hosoya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hosoya-Ohmura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Camper</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning</article-title>
          <source>J. Clin. Invest</source>
          <year>2012</year>
          <volume>122</volume>
          <fpage>3705</fpage>
          <lpage>3717</lpage>
          <pub-id pub-id-type="pmid">22996665</pub-id>
        </element-citation>
      </ref>
      <ref id="b55">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vicente</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vazquez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Conchillo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garcia-Sanchez</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Marcotegui</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities</article-title>
          <source>Leukemia</source>
          <year>2012</year>
          <volume>26</volume>
          <fpage>550</fpage>
          <lpage>554</lpage>
          <pub-id pub-id-type="pmid">21904383</pub-id>
        </element-citation>
      </ref>
      <ref id="b56">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ayala</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Martinez-Lopez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Albizua</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Diez</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Gilsanz</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia</article-title>
          <source>Am. J. Hematol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>79</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">19097174</pub-id>
        </element-citation>
      </ref>
      <ref id="b57">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>West</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Cuellar-Rodriguez</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Hickstein</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation</article-title>
          <source>Haematologica</source>
          <year>2013</year>
          <volume>99</volume>
          <fpage>276</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">24077845</pub-id>
        </element-citation>
      </ref>
      <ref id="b58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickinson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Milne</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jardine</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zandi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Swierczek</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>McGovern</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The evolution of cellular deficiency in GATA2 mutation</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>123</volume>
          <fpage>863</fpage>
          <lpage>874</lpage>
          <pub-id pub-id-type="pmid">24345756</pub-id>
        </element-citation>
      </ref>
      <ref id="b59">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>QH</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>XD</given-names>
            </name>
          </person-group>
          <article-title>Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>2076</fpage>
          <lpage>2081</lpage>
          <pub-id pub-id-type="pmid">18250304</pub-id>
        </element-citation>
      </ref>
      <ref id="b60">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism</article-title>
          <source>Leuk. Res</source>
          <year>2009</year>
          <volume>33</volume>
          <fpage>1141</fpage>
          <lpage>1143</lpage>
          <pub-id pub-id-type="pmid">19304323</pub-id>
        </element-citation>
      </ref>
      <ref id="b61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Harigae</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sugawara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takasawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Kaku</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia</article-title>
          <source>Br. J. Haematol</source>
          <year>2001</year>
          <volume>113</volume>
          <fpage>52</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">11328281</pub-id>
        </element-citation>
      </ref>
      <ref id="b62">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>GATA-1, -2 and -3 genes expression in bone marrow microenviroment with chronic aplastic anemia</article-title>
          <source>Hematology</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>331</fpage>
          <lpage>335</lpage>
          <pub-id pub-id-type="pmid">17654061</pub-id>
        </element-citation>
      </ref>
      <ref id="b63">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nishio</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Muramatsu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Downregulation of GATA-2 and overexpression of adipogenic gene-PPARgamma in mesenchymal stem cells from patients with aplastic anemia</article-title>
          <source>Exp. Hematol</source>
          <year>2009</year>
          <volume>37</volume>
          <fpage>1393</fpage>
          <lpage>1399</lpage>
          <pub-id pub-id-type="pmid">19772889</pub-id>
        </element-citation>
      </ref>
      <ref id="b64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pasquet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bellanne-Chantelot</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tavitian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Prade</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Beaupain</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Larochelle</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>121</volume>
          <fpage>822</fpage>
          <lpage>829</lpage>
          <pub-id pub-id-type="pmid">23223431</pub-id>
        </element-citation>
      </ref>
      <ref id="b65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuellar-Rodriguez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gea-Banacloche</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Zerbe</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>3715</fpage>
          <lpage>3720</lpage>
          <pub-id pub-id-type="pmid">21816832</pub-id>
        </element-citation>
      </ref>
      <ref id="b66">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cuellar-Rodriguez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gea-Banacloche</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zerbe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Nonmyeloablative allogeneic hematopoietic stem-cell transplantation for GATA2 deficiency</article-title>
          <source>Biol. Blood Marrow Transplant</source>
          <year>2014</year>
          <comment>, et al. S1083&#x2013;8791(14):00503&#x2013;5</comment>
        </element-citation>
      </ref>
      <ref id="b67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holme</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hossain</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kirwan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Walne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vulliamy</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Dokal</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia</article-title>
          <source>Br. J. Haematol</source>
          <year>2012</year>
          <volume>158</volume>
          <fpage>242</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="pmid">22533337</pub-id>
        </element-citation>
      </ref>
      <ref id="b68">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gimenez-Sanchez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cobos-Carrascosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sanchez-Forte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinez-Lirola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez-Ruzafa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Galera-Martinez</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Different penetrance of disseminated infections caused by non-tuberculous mycobacteria in mendelian susceptibility to mycobacterial disease associated with a novel mutation</article-title>
          <source>Pediatr. Infect. Dis. J</source>
          <year>2013</year>
          <volume>33</volume>
          <fpage>328</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="pmid">24064560</pub-id>
        </element-citation>
      </ref>
      <ref id="b69">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machaczka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lorenz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kleinotiene</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bulanda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Markuszewska-Kuczynska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raistenskis</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Recurrent pulmonary aspergillosis and mycobacterial infection in an unsplenectomized patient with type 1 Gaucher disease</article-title>
          <source>Ups. J. Med. Sci</source>
          <year>2013</year>
          <volume>119</volume>
          <fpage>44</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">24195576</pub-id>
        </element-citation>
      </ref>
      <ref id="b70">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quispel</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Stegehuis-Kamp</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>van Wengen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dompeling</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Egeler</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Intact IFN-gammaR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease</article-title>
          <source>J. Clin. Immunol</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>600</fpage>
        </element-citation>
      </ref>
      <ref id="b71">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alders</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mendola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ades</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Al Gazali</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bellini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dallapiccola</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of clinical manifestations in patients with severe lymphedema with and without CCBE1 mutations</article-title>
          <source>Mol. Syndromol</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>107</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="pmid">23653581</pub-id>
        </element-citation>
      </ref>
      <ref id="b72">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edeer Karaca</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Boisson-Dupuis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aksu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bustamante</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kandiloglu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ozsan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Granulomatous skin lesions, severe scrotal and lower limb edema due to mycobacterial infections in a child with complete IFN-gamma receptor-1 deficiency</article-title>
          <source>Immunotherapy</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>1121</fpage>
          <lpage>1127</lpage>
          <pub-id pub-id-type="pmid">23194362</pub-id>
        </element-citation>
      </ref>
      <ref id="b73">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gordon</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schulte</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Roukens</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>van Impel</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema</article-title>
          <source>Circ. Res</source>
          <year>2013</year>
          <volume>112</volume>
          <fpage>956</fpage>
          <lpage>960</lpage>
          <pub-id pub-id-type="pmid">23410910</pub-id>
        </element-citation>
      </ref>
      <ref id="b74">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itoh</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Nakagawa</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>A novel complex insertion-deletion mutation in the FOXC2 gene in a Japanese patient with Lymphedema-Distichiasis Syndrome</article-title>
          <source>Eur. J. Dermatol</source>
          <year>2013</year>
          <volume>23</volume>
          <fpage>411</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">23747797</pub-id>
        </element-citation>
      </ref>
      <ref id="b75">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mendola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schlogel</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ghalamkarpour</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Irrthum</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Fastre</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema</article-title>
          <source>Mol. Syndromol</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>257</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">24167460</pub-id>
        </element-citation>
      </ref>
      <ref id="b76">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Conlin</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aagenaes</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Eiklid</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Knisely</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>CCBE1 mutation in two siblings, one manifesting lymphedema-cholestasis syndrome, and the other, fetal hydrops</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e75770</fpage>
          <pub-id pub-id-type="pmid">24086631</pub-id>
        </element-citation>
      </ref>
      <ref id="b77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Motoi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tsuchihashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tazawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nei</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB</article-title>
          <source>J. Med. Genet</source>
          <year>2011</year>
          <volume>48</volume>
          <fpage>205</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">21075760</pub-id>
        </element-citation>
      </ref>
      <ref id="b78">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyde</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>GATA2 mutations lead to MDS and AML</article-title>
          <source>Nat. Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>926</fpage>
          <lpage>927</lpage>
          <pub-id pub-id-type="pmid">21956389</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
